These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 20842955

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M.
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [Abstract] [Full Text] [Related]

  • 8. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 9. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G, Putz R, Szabó D, Molnár K, Bodánszky H, Dezsofi A, Arató A.
    Orv Hetil; 2009 Oct 04; 150(40):1858-60. PubMed ID: 19789146
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb 04; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 04; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.
    J Crohns Colitis; 2011 Aug 04; 5(4):324-31. PubMed ID: 21683302
    [Abstract] [Full Text] [Related]

  • 14. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
    Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z.
    Dig Dis; 2006 Aug 04; 24(1-2):201-6. PubMed ID: 16699279
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, Rossini FP.
    Eur J Dermatol; 2003 Aug 04; 13(3):258-60. PubMed ID: 12804985
    [Abstract] [Full Text] [Related]

  • 16. Long-term infliximab treatment for Behçet's disease.
    Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H.
    Jpn J Ophthalmol; 2007 Aug 04; 51(3):239-40. PubMed ID: 17554493
    [No Abstract] [Full Text] [Related]

  • 17. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
    Dideberg V, Théâtre E, Farnir F, Vermeire S, Rutgeerts P, De Vos M, Belaiche J, Franchimont D, Van Gossum A, Louis E, Bours V.
    Pharmacogenet Genomics; 2006 Oct 04; 16(10):727-34. PubMed ID: 17001292
    [Abstract] [Full Text] [Related]

  • 18. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J.
    Scand J Gastroenterol; 2002 Jul 04; 37(7):818-24. PubMed ID: 12190096
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies].
    Belaiche J, Louis E.
    Rev Med Liege; 2000 Sep 04; 55(9):827-32. PubMed ID: 11105596
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep 04; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.